QS Research · Michael Burry's Scion Capital analyst template · 2006
IONIS PHARMACEUTICALS INC (IONS)
As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data
Report price $28.01 (close 2026-11-16); latest close $26.58 (2026-11-20), -5.1% since the report; figures re-marked at the latest close
Conclusion: PASS
Conviction low · base case -31% · downside -52% · upside +28%
At $28.01 the market pays $5.03B of enterprise value, 5.23x trailing revenue of $960.1M, for a business that lost $564.9M at the operating line and burned $616.3M of free cash flow over the same twelve months. The base case is $18.32, -34.6%, on EV/Sales at 3.55x, the peer median EV/Sales; the downside is $12.82, -54.2%, on the base case's multiple on -30.0% earnings (the peers trade below the compressed multiple); the upside is $34.05, +21.5%, on +20% sales at today's EV/Sales of 5.23x. The de-rating is real—4.86x price/sales sits below the five-fiscal-year median of 9.1x—but that history priced a company with no positive operating year from FY2020 to the trailing twelve months. The reverse DCF needs only -1.2% revenue a year for ten years, well below the +33.8% just delivered, yet a 20% FCF margin that does not exist. With the base below the price, the cash-flow bridge unbuilt, and a $1.88B cash pile making the story binary on a Q4 2026 EU decision, WATCH is the call at low conviction; short interest is already 12.9% of the float.
Key numbers
- Share price: $26.58
- Market cap: $4.43B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $960.1M
- FCF yield: -13.9%
- Price / book: 11.25x
- Earnings-quality flags (TTM): none flagged
- Revenue growth (latest fiscal year): +33.8%
- ROIC (TTM): -43.5%
- WACC: 5.3%
- Economic profit spread: -48.8 pts
The 15 boxes
- ✓ 1. Long-form business notes
IONIS makes money from seven marketed RNA medicines—two now launched independently in the U.S. and several partnered—plus partner royalties and collaboration economics; FY2025 revenue was $944 million with $2.7 billion of cash, cash equivalents and short-term investments. The FY2020-FY2025 cycle shows revenue recovering to $943.7M in FY2025 and $960.1M TTM to Sep 2026, but operating losses and operating cash burn widened, with TTM operating income -$564.9M and TTM operating cash flow -$544.4M. Net income is negative in every supplied period, so normalized valuation should rest on operating and cash-flow trends, not net income.
- ✓ 2. Competitive advantage
The numbers show no durable advantage: revenue went from $729.3M (FY2020) to $943.7M (FY2025) and $960.1M (TTM to 2026-09-30), yet operating income was negative in every one of those periods and reached -$564.9M on the TTM basis, with operating cash flow of -$544.4M TTM. The company's own competition disclosure names approved or late-stage rivals for every marketed medicine — including oral products in HAE and ATTR — and its risk factors state that competitors have substantially greater financial, technical and human resources while IONIS has limited independent commercialization and commercial-scale oligonucleotide manufacturing experience. No source claims brand, cost, network, switching-cost or scale advantage; the only stated differentiation is the chemistry, delivery and behaviour of the medicines versus traditional small molecules, and that claim carries no supporting financial metric.
- ✓ 3. 10-Q takeaways
Q3 2026 total revenue was $243M versus $157M in Q3 2025, but the mix shifted to $48M of product sales (DAWNZERA $37M, TRYNGOLZA $9M, ZANVASTRO $2M) plus $107M of R&D revenue, and the quarter still lost $(130)M from operations on a GAAP basis, $(87)M non-GAAP. Nine-month 2026 revenue of $757M barely exceeded the $740M of the nine months to Sep 2025 because that prior period contained the $280M sapablursen upfront payment, and the nine-month operating loss widened to $(350)M from $(167)M as operating expenses rose to $1,107M from $907M. FY2026 guidance is reaffirmed at $875-900M total revenue, a $425-475M non-GAAP operating loss and cash above $1.6B, with TRYNGOLZA product sales guidance cut to about $50M from $100-110M and DAWNZERA held at $110-120M. Cash fell to $1.9B at Sep 30, 2026 from $2.7B at Dec 31, 2025 after the April 1, 2026 convertible repayment.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.